Mode
Text Size
Log in / Sign up
Phase 4 N=170 Randomized Single-blind Treatment

Low-Dose Versus High-Dose Oxytocin Dosing for Induction and Augmentation of Labor

Labor Long

Enrolled (actual)
170
Serious AEs
0.0%
Results posted
Jan 2026
Primary outcome: Primary: Time to Delivery — 1041.8; 971.1 minutes

Study Design & Population

Study type
Interventional
Phase
Phase 4
Interventions
Oxytocin (Low dose) (Drug); Oxytocin (High dose) (Drug)
Age
Adult · 18+ yrs
Sex
Female
Sponsor
The University of Texas Medical Branch, Galveston
Primary completion
Dec 2024

Outcome Measures

OutcomeResultp-value
PRIMARY
Time to Delivery
1041.8; 971.1
SECONDARY
Mode of Delivery
58; 52; 25; 1; 1; 32
SECONDARY
Rate of Primary Cesarean Delivery
25; 1
SECONDARY
Maximum Dose of Oxytocin Infusion
11.8; 15.6
SECONDARY
Rate of Uterine Tachysystole
15; 22
SECONDARY
Number of Participants With Postpartum Hemorrhage
1; 4
SECONDARY
Rate of Placental Abruption
0; 0
SECONDARY
Number of Participants With Nausea/Vomiting Requiring Antiemetics and Diarrhea
0; 0
SECONDARY
Rate of Maternal Infection (Endometritis, Chorioamnionitis)
29; 30
SECONDARY
Rate of Serious Maternal Morbidity and Mortality
0; 0
SECONDARY
Number of Neonates With One or More of: Perinatal Death, Severe Respiratory Distress Requiring Ventilation, Neonatal Encephalopathy, Neonatal Seizure, Neonatal Sepsis, 5-minute APGAR Score <7, Umbilical Artery Acidemia, Neonatal ICU Admission
7; 10
SECONDARY
Number of Participants With Neonatal Sepsis (Confirmed With Cultures)
0; 0
SECONDARY
Rate of Umbilical Artery Acidemia (Base Excess <12)
0; 1

Summary

The goal of this clinical trial is to compare oxytocin infusion rates for induction and augmentation of labor in nulliparous women. The main question[s] it aims to answer are: * Does a high dose oxytocin infusion protocol affect length of induction to delivery interval? * Does a high dose oxytocin infusion protocol affect mode of delivery? * Does a high dose oxytocin infusion protocol affect maternal and neonatal outcomes? Participants will be randomized to either low- or high-dose oxytocin groups: * The low dose group will receive an infusion to start at 2 milli-units/min and will be increased by 2 milli-units/min every 20 minutes. The maximum rate of infusion is 40 milli-units/min. * The high dose group will receive an infusion to start at 6 milli-units/min and will be increased by 6 milli-units/min every 20 minutes. Maximum rate of infusion is 40 milli-units/min.

Eligibility Criteria

Inclusion Criteria

  • Women aged 18-50 years old
  • Singleton gestation
  • Nulliparous
  • Vertex presentation
  • Gestational age greater than or equal to 37 weeks
  • No prior uterine surgery
  • Presents for elective or medically indicated induction of labor
  • Need for augmentation of labor with oxytocin

Exclusion Criteria

  • Previous cervical ripening using non-mechanical methods
  • Patient unable or unwilling to provide verbal consent
  • Contraindications to vaginal delivery
  • Fetal demise or life-limiting anomaly
  • Allergy to oxytocin
  • Non-reassuring fetal heart tracing prior to inclusion
  • Maternal pulmonary edema prior to inclusion
  • Fetal growth restriction
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT05782816). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search